Verge Genomics Signs a Collaboration Agreement with Ferrer for the Development and Commercialization of VRG50635 to Treat Amyotrophic Lateral Sclerosis (ALS)
Shots:
- The companies signed an agreement to co-develop & commercialize Verge’s VRG50635 for the treatment of sporadic and familial forms of ALS across EU, Central & South America, Southeast Asia & Japan
- Under the terms of the agreement, Ferrer received the exclusive rights to co-develop & commercialize VRG50635 across multiple regions outside the US whereas Verge retains all the development and commercialization rights for all uses in the US & all countries outside the agreement
- VRG50635 is a small molecule inhibitor of PIKfyve (developed using an AI-enabled platform) & is currently being evaluated in a P-I PoC study across Canada & various European Countries for safety, efficacy & pharmacological dose-response
Ref: Globenewswire | Image: Verge Genomics
Related News:- Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
